20 (AIDX) Cash & Current Investments (2024 - 2026)

20 (AIDX) posted Cash & Current Investments of $4.2 million for Q1 2026, up 311.22% on a QoQ basis from $1.0 million in Q4 2025.

20 (AIDX) Cash & Current Investments (2024 - 2026) Analysis & Trends

20's Cash & Current Investments history runs 3 years deep, the most recent figure standing at $4.2 million for Q1 2026.

Quarterly Cash & Current Investments changed N/A year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 million (changed N/A YoY) and the FY2025 annual result came in at $1.0 million, down 42.49% from the prior year.
Cash & Current Investments was $4.2 million for Q1 2026 at 20, up from $1.0 million in the prior quarter.
Across five years, Cash & Current Investments topped out at $4.2 million in Q1 2026 and bottomed at $1.0 million in Q4 2025.
A 3-year average of $2.3 million and a median of $1.8 million in 2024 frame the typical range for Cash & Current Investments.
Peak annual rise in Cash & Current Investments reached 42.49% in 2025, while the deepest fall reached 42.49% in 2025.
20's Cash & Current Investments stood at $1.8 million in 2024, then plunged by 42.49% to $1.0 million in 2025, then soared by 311.22% to $4.2 million in 2026.
Business Quant data shows AIDX's Cash & Current Investments at $4.2 million in Q1 2026, $1.0 million in Q4 2025, and $1.8 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash & Current Investments (Qtr)
1	Abbott Laboratories	183.54 Bn	176.25 Bn	6.27 Bn	7.30 Bn
2	Stryker	128.93 Bn	126.05 Bn	3.81 Bn	2.88 Bn
3	Medtronic	108.84 Bn	99.62 Bn	6.41 Bn	9.22 Bn
4	Boston Scientific	68.42 Bn	66.96 Bn	3.61 Bn	1.45 Bn
5	Edwards Lifesciences	47.32 Bn	43.65 Bn	1.29 Bn	3.67 Bn
6	GE HealthCare Technologies	28.46 Bn	26.18 Bn	1.98 Bn	2.29 Bn
7	Dexcom	28.46 Bn	27.34 Bn	750.30 Mn	1.12 Bn
8	Smith & Nephew	26.97 Bn	26.40 Bn	-	577.00 Mn
9	Koninklijke Philips	25.55 Bn	22.42 Bn	2.07 Bn	3.12 Bn
10	20	3.48 Mn	-734,294.08	62,884.00	4.22 Mn

Download Data